<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="style.css">
    <title>ReHopefulstat</title>
</head>

<body>

    <header class="top-content">
        <div class="header head-item">Hepion Pharmaceuticals</div>
        <div class="nav head-item">
            <div class="nav-item">Summary</div>
            <div class="nav-item">Fact Sheet</div>
            <div class="nav-item">Trials</div>
        </div>
    </header>

    <section class="preview">
        <div class="preview-item preview-left">TACKLING CHRONIC LIVER DISEASE:<br>NASH, Hepatitis, Cirrhosis, Liver
            Failure, and Cancer.</div>
        <div class="preview-item preview-right">Hepion Pharmaceuticals is a clinical stage biopharmaceutical company
            focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic
            steatohepatitis, fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases.</div>
    </section>

    <section class="main-content">
        <div class="main-left">
            <h2>Key Points</h2><br>
            <div class="first-letter">Rencofilstat was found to potently inhibit all cyclophilin isoforms tested — A, B, D, and G.</div><br>
            <div class="first-letter">Rencofilstat Binds to Cylophilin A, reduced inflammatory damage to the liver.</div><br>
            <div class="first-letter">Rencofilstat Blocks the Action of Cylophilin B, reduction in collagen secretions and fibrotic scarring.</div><br>
            <div class="first-letter">Rencofilstat Binds to Cylophilin D, decreases cell death in injured livers. </div><br>
        </div>
        <!-- Main Content Section / Divider -->
        <div class="main-right">
            <h2>Recent Press Release / Articles / Findings</h2><br>
            <h4>2023</h4><br>
            <div class="first-letter">January 18 - Anti-Cancer Potential of Rencofilstat with Results from Preclinical Multiple Myeloma Studies.</div>
            <div class="first-letter">January 10 - Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors.</div>
            <br><h4>2022</h4><br>
            <div class="first-letter">December 5 - Announces Early Completion of Enrollment in Phase 2 "ALTITUDE NASH" Liver Function Trial</div>
            <div class="first-letter">October 26 - Publication of Phase 2A AMBITION Clinical Trial Results.</div>
            <div class="first-letter">October 20 - Publication of Food Effect Study with Rencofilstat.</div>
            <div class="first-letter">September 12 - Initiation of Dosing in Phase 2 ALTITUDE-NASH Liver Function Trial</div>
            <div class="first-letter">August 31 - Initiation of Phase 2B ASCEND-NASH Trial</div>
            <div class="first-letter">June 20 - Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma.</div>
            <div class="first-letter">May 3 - Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial</div>
            <div class="first-letter">January 26 - Rencofilstat with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity.</div>
            <div class="first-letter">January 6 - Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431</div>
            <br><h4>2021</h4><br>
            <div class="first-letter">December 21 - Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer.</div>
            <div class="first-letter">November 30 - Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH.</div>
            <div class="first-letter"> November 16 - FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study.</div>
            <div class="first-letter">September 29 - All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431.</div>
            <div class="first-letter">July 13 - Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved.</div>
            <div class="first-letter">June 9 - Hepion Pharmaceuticals to be Added to the Russell Microcap® Index.</div>
            <div class="first-letter">May 6 - Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ Clinical Trial of CRV431 for the Treatment of Advanced NASH.</div>
            <div class="first-letter">March 23 - DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431.</div>
            <div class="first-letter">February 12 - Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock.</div>
        </div>

    </section>
</body>

</html>